Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

France's Adocia Completes 2012's First Euro Biotech IPO

This article was originally published in The Pink Sheet Daily

Executive Summary

French drug delivery company, Adocia, raises $33 million to develop new formulations of therapeutic proteins for wound healing, diabetes

You may also be interested in...



As The World Turns: Cash Raised In France Could Get Vaccines Developed In Cuba Marketed In Asia

Abivax’s record-breaking IPO will support development of a therapeutic vaccine against hepatitis B and an antiviral against HIV/AIDS, and the distribution of a series of Cuba-marketed vaccines in Asia.

Adocia Targeting Insulin Combos After Ultra-Fast Insulin Deal With Lilly

A concentrated insulin formulation and extra clinical data were instrumental in Lilly’s second deal on the use of Adocia’s BioChaperone technology for an ultra-fast-acting insulin, with the latest agreement between the two companies providing funds for Adocia to pursue other insulin research areas.

European Biotechs Mull Going To Market Without Big Pharma Partners

European biotech companies that have lead products turned down by big pharma are now considering the benefits of taking drugs through late-stage development themselves; more funding options, such as concluding an IPO in the U.S. or Europe, is driving some of this change.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS073764

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel